article
Pharmaceutical C-suite update
With two knighthoods in the last month, here EPR discusses…
With two knighthoods in the last month, here EPR discusses five developments in the drug development community’s C-suite.
List view / Grid view
Pascal Soriot
news
AstraZeneca announces new site plans at innovation hub
AstraZeneca has announced plans to invest in a new facility,…
AstraZeneca has announced plans to invest in a new facility, uniting its R&D activities with commercial and corporate functions in Boston, US.
![AstraZeneca sign and logo on company building exterior - South San Francisco, California, US in 2020 [Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/AstraZeneca-4-300x278.jpg)
![AstraZeneca sign and logo on company building exterior - South San Francisco, California, US in 2020 [Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/AstraZeneca-4.jpg)
news
AstraZeneca reveals $15.54 billion in revenues in H1 2021
H1 financial results show AstraZeneca’s revenues grew by 23 percent…
H1 financial results show AstraZeneca’s revenues grew by 23 percent in 2021, with $14.37 billion attributed to activities aside from COVID-19 vaccine sales.
news
AstraZeneca to provide EU with extra nine million doses of COVID-19 vaccine following dispute
After manufacturing delays, AstraZeneca will now provide the EU with…
After manufacturing delays, AstraZeneca will now provide the EU with the 40 million COVID-19 vaccine doses it originally agreed to supply.
news
AZD1222 vaccine for COVID-19 is safe and effective in Phase III trials
Interim analysis shows AZD1222 vaccine is effective at preventing COVID-19,…
Interim analysis shows AZD1222 vaccine is effective at preventing COVID-19, with no severe cases or hospitalisations reported more than 21 days after first injection.
news
Clinical trials to study AstraZeneca’s COVID-19 vaccine resume globally
Clinical trials for AZD1222, the AstraZeneca COVID-19 vaccine candidate, have…
Clinical trials for AZD1222, the AstraZeneca COVID-19 vaccine candidate, have resumed across the world after confirmation it is safe to do so.
news
Clinical trial for AstraZeneca Oxford COVID-19 vaccine candidate to resume
After the clinical trial for AZD1222 was halted last week,…
After the clinical trial for AZD1222 was halted last week, the studies for AstraZeneca's COVID-19 vaccine candidate will now resume.
news
AstraZeneca to supply Europe with up to 400 million doses of COVID-19 vaccine
An agreement between AstraZeneca and the European Commission means the…
An agreement between AstraZeneca and the European Commission means the company will supply up to 400 million doses of its AZD1222 COVID-19 vaccine.
news
AstraZeneca commits to supply Europe with 400 million doses of COVID-19 vaccine candidate
AstraZeneca plans to produce up to 400 million doses of…
AstraZeneca plans to produce up to 400 million doses of the University of Oxford’s COVID-19 vaccine candidate, with deliveries to begin by the end of the year.
article
Radical innovation occurs when pharma looks outside its own world
Pharma executives are committed to bringing drugs to market to…
Pharma executives are committed to bringing drugs to market to improve the lives of patients but is the industry too introspective to be truly innovative?
news
Gavi launches $2 billion COVID-19 vaccine funding initiative
The vaccine alliance said the Covax AMC programme is the…
The vaccine alliance said the Covax AMC programme is the first in a series of financing programmes to ensure low- and middle-income countries will have access to COVID-19 vaccines.
news
University of Oxford and AstraZeneca sign deal to produce COVID-19 vaccine
A new agreement between the University of Oxford and AstraZeneca…
A new agreement between the University of Oxford and AstraZeneca will allow the former's COVID-19 vaccine candidate to be manufactured and distributed.
news
AstraZeneca announces plan for zero carbon emissions by 2025
AstraZeneca’s new carbon emission plan includes a 100 percent electric…
AstraZeneca’s new carbon emission plan includes a 100 percent electric vehicle fleet and a 50 million tree reforestation plan.
news
FDA approves Fasenra for severe eosinophilic asthma
The FDA has approved Fasenra for the add-on maintenance treatment of…
The FDA has approved Fasenra for the add-on maintenance treatment of patients with severe asthma aged 12 years and older...
news
AstraZeneca to acquire 55% stake in Acerta Pharma
Following the news earlier this week that AstraZeneca had been…
Following the news earlier this week that AstraZeneca had been in acquisition talks with Acerta Pharma, AstraZeneca today announced that it is to invest in a majority equity stake in the company.
